2025-06-05-Jefferies-Vaxcyte（PCVX）_PCVX在杰富瑞2025年医疗保健会议_成人3期试验启动_婴儿项目进展_8页_111kb

报告摘要

Vaxcyte Company Overview

Vaxcyte is a next-generation vaccine company focusing on developing superior vaccines for pneumococcal disease prevention. The company has a strong financial position with approximately $3 billion in cash, supporting clinical development and commercial build-up for several years.

Adult Program (VAX-31)

VAX-31 is in Phase 3 pivotal trials for adults, set to start mid-2025 with topline data expected in 2026.
Non-inferiority pathway supported by Breakthrough Therapy Designation (BTD), enabling frequent FDA engagement.
Market opportunity: Global PCV market is $8B, with adults representing about 25% share and growth potential due to age cutoff changes.
Unique approach: High-dose strategy focuses on immunogenicity, positioning Vaxcyte as a leader; major pharma companies are responding with similar programs, but Vaxcyte has a head start using its carrier-sparing platform.

Infant Program (VAX-24)

VAX-24 infant program is progressing with higher doses (3.3-4.4 mcg) aimed at improving immune responses.
March 2025 readout showed consistent safety and strong immunogenicity; non-inferiority misses narrowly occurred but will be addressed through dose increases.
Full Phase 2 data expected end-2025, with potential for the company to decide on Phase 3 initiation based on VAX-31 Phase 2 data mid-2026.
VAX-24 learns are being incorporated into VAX-31, with a plan for flexibility in future doses to enhance effectiveness.

Market Potential

Global PCV market is $8B with opportunities in adults and broader PCV uptake in international markets.
TAM expansion: US ACIP lowered the age cutoff for PCV recipients to 50+, adding 65M eligible Americans.
Outside US, broader-spectrum PCVs are gaining traction, setting up for significant adult uptake.

Competitive Advantages

Carrier-sparing conjugation platform reduces carrier suppression, allowing higher antigen doses and better immunogenicity in vulnerable populations.
Broader serotype coverage (95% vs. ~60% for competitors) drives adoption by physicians and policymakers.
Modular chemistry enables rapid development of future vaccine valencies, supporting long-term franchise durability.

Investment Case

Equity Research: BUY rating with price target $146, potential +320% upside, based on a DCF model.
Analysts highlight strong regulatory engagement, positive market growth, and platform strengths as key growth drivers.

Key Risks

Development, manufacturing, regulatory, and commercial risks, including potential setbacks in non-inferiority data or competition from other programs.

This summary captures the core findings from the Jefferies Equity Research report on Vaxcyte Inc.

展开完整摘要